Serum to urinary prostate specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer

This study was designed to evaluate the serum to urinary PSA ratio as new parameter for early detection of prostate cancer in addition to serum PSA. The study included 40 patients; 30 patients with BPH, 10 patients with prostate carcinoma and 10 control subjects. Serum PSA was measured by VIDAS whereas urinary PSA was measured by a double antibody radioimmunoassay and serum-to-urinary PSA ratio was calculated. It was sfound that serum-to-urinary PSA ratio can discrimininate between prostate cancer and BPH in event of a lack of significant difference between the serum PSA levels. We suggest that the concept of serum-to-urinary PSA ratio offer a new parameter for early detection of prostate cancer in addition to total serum PSA

Treatment of simple renal cysts with ethanol sclerotherapy

32 simple renal cysts in 28 patients were diagnosed and punctured using computerized sonographic machine and then treated with 95% ethanol, also followed up by ultrasound, from 3 to 12 months. The size of all cysts were decreased except there was one recurrence at 3 months. Minor complications of hematuria and temperature elevation, which is the same as with diagnostic aspiration alone. There was no major complication

use of Prostatron for management of benign prostatic hyperplasia [BPH]

98 patients with BPH were treated with transurethral microwave thermotherapy [Prostatrone Technomed International, France], by single session for 60 minutes with cooling of the urethra and high therapeutic power 45C - 55C. All those patients were followed up for 3 months, 71 patients for 6 months, 56 patients for 12 months and 39 patients for 18 months. At 3 months 61 patients [62.2%] showed success of treatment, 27 patients [27.6%] showed symptomatic improvement and 10 patients [10.2%] showed failed treatment. At 6 months, 48 patients [67.6%] showed success, 5 patients [7%] failure and 18 patients [25.4%] showed symptomatic improvement. After 12 months 37 patients [66%] showed success, 3 patients [5.4%] failure and 16 patients [33.3%] showed symptomatic improvement. At 18 months follow up, 25 patients [64.1%] showed success, 13 patients [33.3%] showed symptomatic improvement and one patient failure. No significant major complication encountered